BioCryst Q2 revenue $218.3M, GAAP operating profit $98.5M; raises total revenue guidance

BIOCRYST PHARMACEUTICALS INC

ORLADEYO net revenue $158.2M (+1% YoY); oral pellets shipping to pediatric patients began Aug 3.
GAAP operating profit $98.5M; non-GAAP operating profit $113.2M; cash $354M.
Raised FY2026 total revenue guidance to $690-715M; ORLADEYO guidance unchanged $625-645M.
Completed enrollment in navenibart pivotal study (ALPHA-ORBIT); top-line data expected Q3 2027.
Licensed navenibart European rights to Neopharmed Gentili for $70M upfront plus milestones/royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.